S1438
Sulindac sulfone
≥94% (HPLC), (solid or powder)
别名:
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfonyl)benzylidene]indene-3-acetic acid
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H17FO4S
化学文摘社编号:
分子量:
372.41
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Assay:
≥94% (HPLC)
Form:
(solid or powder)
Quality Segment
assay
≥94% (HPLC)
form
(solid or powder)
color
, Light Yellow to Dark Yellow
solubility
DMSO: >25 mg/mL, ethanol: 3 mg/mL (warm), acetone: 5 mg (plus 0.1 ml)
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
SMILES string
CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C\c3ccc(cc3)S(C)(=O)=O
InChI
1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+
InChI key
MVGSNCBCUWPVDA-RQZCQDPDSA-N
Application
Human endothelial cells, HMEC-1 were treated with Sulindac sulfone and the effect on cell survival was studied by MTT assay.
Biochem/physiol Actions
Metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. Inhibits the development and induces regression of premalignant adenomatous polyps.
Sulindac sulfone is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells1,2 and reduces tumor burden in adenomatous polyposis patients.3
Features and Benefits
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Sulindac sulfone yields clear, light yellow to dark yellow solution in acetone at 50 mg/ml.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)